Dysregulation of Microrna Expression in Acquired Endocrine- Resistant Breast Cancer

Total Page:16

File Type:pdf, Size:1020Kb

Dysregulation of Microrna Expression in Acquired Endocrine- Resistant Breast Cancer University of Louisville ThinkIR: The University of Louisville's Institutional Repository Electronic Theses and Dissertations 12-2012 Dysregulation of microRNA expression in acquired endocrine- resistant breast cancer. Tissa Thomas Manavalan University of Louisville Follow this and additional works at: https://ir.library.louisville.edu/etd Recommended Citation Manavalan, Tissa Thomas, "Dysregulation of microRNA expression in acquired endocrine-resistant breast cancer." (2012). Electronic Theses and Dissertations. Paper 897. https://doi.org/10.18297/etd/897 This Doctoral Dissertation is brought to you for free and open access by ThinkIR: The University of Louisville's Institutional Repository. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of ThinkIR: The University of Louisville's Institutional Repository. This title appears here courtesy of the author, who has retained all other copyrights. For more information, please contact [email protected]. DYSREGULATION OF MICRORNA EXPRESSION IN ACQUIRED ENDOCRINE-RESISTANT BREAST CANCER By Tissa Thomas Manavalan B.Sc., Bangalore University, 2005 M.Sc., Bangalore University, 2007 M.S., University of Louisville, 2011 A Dissertation Submitted to the faculty of the University of Louisville School of Medicine In Partial Fulfillments of the Requirements For the Degree of Doctor of Philosophy Department of Biochemistry and Molecular Biology University of Louisville, School of Medicine Louisville, KY December 2012 Copyright 2012 by Tissa Thomas Manavalan All rights reserved DYSREGULATION OF MICRORNA EXPRESSION IN ACQUIRED ENDOCRINE-RESISTANT BREAST CANCER By Tissa T. Manavalan B.Sc., Bangalore University, 2005 M.Sc., Bangalore University, 2007 M.S., University of Louisville, 2011 A Dissertation Approved on September 20, 2012 by the following Thesis Committee: Dr. Carolyn M. Klinge (Mentor) Dr. Barbara J. Clark Dr. Yong Li Dr. Robert A. Mitchell Dr. Theodore S. Kalbfleisch ii DEDICATION This dissertation is dedicated to my parents for their constant love, encouragement and support over the course of my life and my Ph.D. program. I would also like to dedicate this to my husband, Roshan James for his motivation that helped in the completion of my graduate studies. 111 ACKNOWLEDGEMENTS I am sincerely grateful to my mentor, Dr. Carolyn Klinge for her encouragement and support for the successful completion of my Ph.D. Her guidance was invaluable for my doctoral work. I would also like to convey my sincere thanks to my committee members, Dr. Barbara Clark, Dr. Y ong Li, Dr. Robert Mitchell and Dr. Ted Kalbfleisch for their valuable comments and advice towards the project. I would like to thank the members of the Klinge laboratory for their support and assistance over the years. A special thanks to Dr. Nalinie Wickramasinghe, a past member of the lab, for her guidance in the initial years of my Ph.D. iv ABSTRACT DYSREGULA nON OF MICRORNA EXPRESSION IN ACQUIRED ENDOCRINE-RESISTANT BREAST CANCER Tissa T. Manavalan September 20, 2012 MicroRNAs (miRNAs) regulate gene expression at the post-transcriptional level by repressing translation or stimulating mRNA degradation. In this study, I tested the hypothesis that miRNAs are differentially expressed in antiestrogen­ sensitive MCF-7 versus -resistant LY2 human breast cancer cells. Microarray analyses identified 97 miRNAs that are differentially expressed between two estrogen receptor alpha (ERa) -positive human breast cancer cell lines: endocrine-sensitive MCF-7 versus -resistant LY2 cells under basal conditions. Opposite expression of miRs-lOa, -21, -22, -12Sb, -181, -200a, -200b, -200c, -221, and -222 was confirmed between MCF-7 and LY2 cells. The ER antagonist ICI 182,780 (fulvestrant or Faslodex) generally blocked the effect of estradiol E2 and 4-hydroxytamoxifen (4- OHT) regulated miRs, i.e .. , miR-lOa, miR-21, miR-22, miR-200a, miR-221, and miR- 222, indicating that these responses in MCF-7 cells are ER-mediated. Time­ dependent variation in basal (ethanol, the vehicle), E2, and 4-0HT regulation of the top 8 miRNAs was detected in MCF-7 cells. Bioinformatic analyses to impute the biological significance of the identified miRNAs by identifying their computationally predicted target genes in the human genome using TargetScan, Pic Tar, and the Sanger v miRBase Targets databases was performed. Thirty six putative mRNA targets were identified. Agreement in the direction of anticipated regulation was detected for 12 putative targets. These miRNAs showing opposite expression between these two breast cancer cell lines may be involved in endocrine resistance. MiR-200 family includes two clusters i.e. miR-200 aJ200bl 429 and miR- 200cl141 encoded on chromosome 1 and chromosome 12, respectively. Lower miR- 200a, miR-200 band miR-200c expression was observed in estrogen-independent LCC1 and endocrine-resistant LCC2, LCC9, and LY2 compared to the parental, endocrine-sensitive MCF-7 human breast cancer cell line. ZEB 1 protein was found to be expressed in endocrine-resistant LY2 cells but not in endocrine-sensitive MCF-7 cells. LY2 cells did not express E-cadherin, a ZEB 1 target which is a marker for epithelial phenotype. This is the first demonstration that LY2 cells have undergone EMT as part of their endocrine-resistant phenotype. Concomitant with miR-200 decrease, there was an increase in ZEB 1 mRNA expressIOn m LY2 cells. Overexpression of miR-200b or miR-200c in LY2 cells changed the cellular morphology from a mesenchymal to an epithelial appearance and sensitized cells to inhibition by 4-0HT and fulvestrant. These studies indicate that reduced expression of miR-200 and a corresponding increase in ZEB 1 protein is an indicator of endocrine-resistance in breast cancer cells. vi TABLE OF CONTENTS DEDICA TION ............................................................................................................ iii ACKNOWLEDGEMENTS ....................................................................................... iv ABSTRACT .................................................................................................................. v TABLE OF CONTENTS .......................................................................................... vii LIST OF TABLES ....................................................................................................... x LIST OF FIGURES .................................................................................................... xi CHAPTER I: INTRODUCTION TO BREAST CANCER ..................................... 1 BREAST CANCER AND ESTROGEN SIGNALING ............................................................................ 1 ENDOCRINE THERAPIES FOR THE TREATMENT OF BREAST CANCER ................................... 3 MECHANISMS OF ENDOCRlNEITAMOXIFEN-RESISTANCE............................ ............................ 6 CHAPTER II: SIGNIFICANCE OF MICRO RNA EXPRESSION IN ENDOCRINEffAMOXIFEN -RESISTANT BREAST CANCER •..••..•....•..•..••••• 12 BIOGENESIS OF MICRORNA ......................................................................................................... 12 MICRORNA FUNCTION .................................................................................................................. 13 REGULATION OF MICRORNA EXPRESSION ............................................................................... 15 MICRORNA AS ONCOGENES OR TUMOR SUPPRESSORS ......................................................... 18 MICRORNA EXPRESSION IN BREAST CANCER ........................................................................... 19 MICRORNAs REGULATE ERaACTIVlTY ...................................................................................... 21 MICRORNA AND ENDOCRINE RESISTANCE ............................................................................... 23 DISSERTATION SPECIFIC AIMS AND HYPOTHESES .................................. 24 vii CHAPTER III: DIFFERENTIAL EXPRESSION OF MICRORNAs IN TAMOXIFEN- SENSITIVE MCF-7 VERSUS TAMOXIFEN-RESISTANT LY2 BREAST CANCER CELLS ..................................................................................... 27 1. INTRODUCTION .......................................................................................................................... 27 2. MATERIALS AND METHODS ...................................................................................................... 30 3. RESULTS AND DISCUSSION ...................................................................................................... 35 identification ofmiRNAs differentially expressed in MCF-7 and LY2 cells. ..................................... 35 Selection of endogenous control genes for Q-PCR normalization and validation of select miRNAs by Q-PCR ............................................................................................................................................... 46 Time course ofmiRNA expression in MCF-7 cells ............................................................................ 54 Time course of E2 and 4-0HT regulation of ERa, ERfJ, and Argonaute-2 (Ag02) ........................... 57 Computational identification ofmiRNA target mRNA genes in 4-0HT-treated MCF-7 cells ........... 60 PDCD4, BCL2, CYPIBI, and ERBB3 are differentially expressed in MCF-7 and LY2 cells ........... 63 ESRI and ERaprotein expression is lower in LY2 than MCF-7 cells .............................................. 67 miR-200-regulated ZEBI is reduced in LY2 cells .............................................................................
Recommended publications
  • Case Report a Fetus with Kabuki Syndrome 2 Detected by Chromosomal Microarray Analysis
    Int J Clin Exp Pathol 2020;13(2):302-306 www.ijcep.com /ISSN:1936-2625/IJCEP0104334 Case Report A fetus with Kabuki syndrome 2 detected by chromosomal microarray analysis Chen-Zhao Lin1, Bi-Ru Qi1, Jian-Su Hu2, Xiu-Qiong Huang3 Departments of 1Obstetrics and Gynecology, 2Ultrasound, 3Laboratory Medicine, Fuzhou Municipal First Hospital Affiliated to Fujian Medical University, Fuzhou 350009, Fujian Province, The People’s Republic of China Received November 1, 2019; Accepted January 26, 2020; Epub February 1, 2020; Published February 15, 2020 Abstract: Background: Kabuki syndrome is a rare multiple congenital anomaly syndrome characterized by distinct facial features, intellectual disability, cardiovascular and musculoskeletal abnormalities, persistence of fetal finger- tip pads, and postnatal growth deficiency. Currently, the diagnosis mainly depends on clinical manifestations and genetic testing. To date, there is no report on the identification Kabuki syndrome in fetuses using chromosomal microarray analysis (CMA). Case presentation: A fetus was identified with growth retardation and cardiovascular abnormality on color Doppler ultrasonography; however, non-invasive prenatal testing (NIPT) revealed a low risk and G-banding karyotyping revealed no abnormal karyotype detected. CMA identified a 1.3 Mb deletion on the X chromosome (Xp11.3) containing KDM6A, DUSP21, MIR222, MIR221 and CXorf36 genes. The fetus was diagnosed with Kabuki syndrome 2, and labor was induced. In addition, CMA detected a 1.3 Mb deletion in the chromosome Xp11.3 in the mother, which contains 5 genes namely KDM6A, DUSP21, MIR222, MIR221 and CXorf36, while no chromosomal abnormality was identified in the father. Conclusions: We report a fetus with Kabuki syndrome 2 detected using CMA.
    [Show full text]
  • The Role of Microrna in Human Leukemia: a Review
    Leukemia (2009) 23, 1257–1263 & 2009 Macmillan Publishers Limited All rights reserved 0887-6924/09 $32.00 www.nature.com/leu SPOTLIGHT REVIEW The role of microRNA in human leukemia: a review S Yendamuri1 and GA Calin2 1Department of Thoracic Surgery, Roswell Park Cancer Institute, Buffalo, NY, USA and 2Department of Experimental Therapeutics, University of Texas MD Anderson Cancer Center, Houston, TX, USA MicroRNAs (miRNAs or miRs) are 18–22-nucleotide non-coding target. If the sequence is a perfect match, the final result seems RNAs that have emerged as a new paradigm of epigenetic to be target mRNA degradation in a manner similar to siRNA- regulation in both normal development and cellular function, and in the pathogenesis of human disease including cancer. induced gene expression silencing. This seems to be the This review summarizes the current literature of mechanism of predominant mechanism in plants. A less than perfect match gene regulation by miRNA and their role in hematopoiesis and may result in inefficient translation leading to effective down- leukemogenesis. An understanding of these processes sug- regulation of the gene, a mechanism more common in gests further avenues for research to understand gene regula- animals.7–9 Isolated examples of miRNA leading to upregulation tion and miRNA-based therapeutic approaches. of genes have been reported.10 Leukemia (2009) 23, 1257–1263; doi:10.1038/leu.2008.382; The mechanism of translational repression is known only published online 15 January 2009 11 Keywords: microRNA; non-coding RNA; microarray; partially. The mRNA segments that miRNAs bind seem to be mostly in the 30UTRs of genes.
    [Show full text]
  • Supplementary Materials
    Supplementary materials Supplementary Table S1: MGNC compound library Ingredien Molecule Caco- Mol ID MW AlogP OB (%) BBB DL FASA- HL t Name Name 2 shengdi MOL012254 campesterol 400.8 7.63 37.58 1.34 0.98 0.7 0.21 20.2 shengdi MOL000519 coniferin 314.4 3.16 31.11 0.42 -0.2 0.3 0.27 74.6 beta- shengdi MOL000359 414.8 8.08 36.91 1.32 0.99 0.8 0.23 20.2 sitosterol pachymic shengdi MOL000289 528.9 6.54 33.63 0.1 -0.6 0.8 0 9.27 acid Poricoic acid shengdi MOL000291 484.7 5.64 30.52 -0.08 -0.9 0.8 0 8.67 B Chrysanthem shengdi MOL004492 585 8.24 38.72 0.51 -1 0.6 0.3 17.5 axanthin 20- shengdi MOL011455 Hexadecano 418.6 1.91 32.7 -0.24 -0.4 0.7 0.29 104 ylingenol huanglian MOL001454 berberine 336.4 3.45 36.86 1.24 0.57 0.8 0.19 6.57 huanglian MOL013352 Obacunone 454.6 2.68 43.29 0.01 -0.4 0.8 0.31 -13 huanglian MOL002894 berberrubine 322.4 3.2 35.74 1.07 0.17 0.7 0.24 6.46 huanglian MOL002897 epiberberine 336.4 3.45 43.09 1.17 0.4 0.8 0.19 6.1 huanglian MOL002903 (R)-Canadine 339.4 3.4 55.37 1.04 0.57 0.8 0.2 6.41 huanglian MOL002904 Berlambine 351.4 2.49 36.68 0.97 0.17 0.8 0.28 7.33 Corchorosid huanglian MOL002907 404.6 1.34 105 -0.91 -1.3 0.8 0.29 6.68 e A_qt Magnogrand huanglian MOL000622 266.4 1.18 63.71 0.02 -0.2 0.2 0.3 3.17 iolide huanglian MOL000762 Palmidin A 510.5 4.52 35.36 -0.38 -1.5 0.7 0.39 33.2 huanglian MOL000785 palmatine 352.4 3.65 64.6 1.33 0.37 0.7 0.13 2.25 huanglian MOL000098 quercetin 302.3 1.5 46.43 0.05 -0.8 0.3 0.38 14.4 huanglian MOL001458 coptisine 320.3 3.25 30.67 1.21 0.32 0.9 0.26 9.33 huanglian MOL002668 Worenine
    [Show full text]
  • Development of Novel Therapeutic Agents by Inhibition of Oncogenic Micrornas
    International Journal of Molecular Sciences Review Development of Novel Therapeutic Agents by Inhibition of Oncogenic MicroRNAs Dinh-Duc Nguyen and Suhwan Chang * ID Department of Biomedical Sciences, University of Ulsan College of Medicine, Asan Medical Center, Seoul 05505, Korea; [email protected] * Correspondence: [email protected] Received: 21 November 2017; Accepted: 22 December 2017; Published: 27 December 2017 Abstract: MicroRNAs (miRs, miRNAs) are regulatory small noncoding RNAs, with their roles already confirmed to be important for post-transcriptional regulation of gene expression affecting cell physiology and disease development. Upregulation of a cancer-causing miRNA, known as oncogenic miRNA, has been found in many types of cancers and, therefore, represents a potential new class of targets for therapeutic inhibition. Several strategies have been developed in recent years to inhibit oncogenic miRNAs. Among them is a direct approach that targets mature oncogenic miRNA with an antisense sequence known as antimiR, which could be an oligonucleotide or miRNA sponge. In contrast, an indirect approach is to block the biogenesis of miRNA by genome editing using the CRISPR/Cas9 system or a small molecule inhibitor. The development of these inhibitors is straightforward but involves significant scientific and therapeutic challenges that need to be resolved. In this review, we summarize recent relevant studies on the development of miRNA inhibitors against cancer. Keywords: antimiR; antagomiR; miRNA-sponge; oncomiR; CRISPR/Cas9; cancer therapeutics 1. Introduction Cancer has been the leading cause of death and a major health problem worldwide for many years; basically, it results from out-of-control cell proliferation. Traditionally, several key proteins have been identified and found to affect signaling pathways regulating cell cycle progression, apoptosis, and gene transcription in various types of cancers [1,2].
    [Show full text]
  • Differential Expression of Micrornas in Adipose Tissue After Long-Term High-Fat Diet-Induced Obesity in Mice
    Differential Expression of MicroRNAs in Adipose Tissue after Long-Term High-Fat Diet-Induced Obesity in Mice Dionysios V. Chartoumpekis1, Apostolos Zaravinos2, Panos G. Ziros1, Ralitsa P. Iskrenova1, Agathoklis I. Psyrogiannis1, Venetsana E. Kyriazopoulou1, Ioannis G. Habeos1* 1 Department of Internal Medicine, Division of Endocrinology, Medical School, University of Patras, Patras, Greece, 2 Laboratory of Clinical Virology, Medical School, University of Crete, Heraklion, Greece Abstract Obesity is a major health concern worldwide which is associated with increased risk of chronic diseases such as metabolic syndrome, cardiovascular disease and cancer. The elucidation of the molecular mechanisms involved in adipogenesis and obesogenesis is of essential importance as it could lead to the identification of novel biomarkers and therapeutic targets for the development of anti-obesity drugs. MicroRNAs (miRNAs) have been shown to play regulatory roles in several biological processes. They have become a growing research field and consist of promising pharmaceutical targets in various fields such as cancer, metabolism, etc. The present study investigated the possible implication of miRNAs in adipose tissue during the development of obesity using as a model the C57BLJ6 mice fed a high-fat diet. C57BLJ6 wild type male mice were fed either a standard (SD) or a high-fat diet (HFD) for 5 months. Total RNA was prepared from white adipose tissue and was used for microRNA profiling and qPCR. Twenty-two of the most differentially expressed miRNAs, as identified by the microRNA profiling were validated using qPCR. The results of the present study confirmed previous results. The up- regulation of mmu-miR-222 and the down-regulation of mmu-miR-200b, mmu-miR-200c, mmu-miR-204, mmu-miR-30a*, mmu-miR-193, mmu-miR-378 and mmu-miR-30e* after HFD feeding has also been previously reported.
    [Show full text]
  • Supplementary Information.Pdf
    Supplementary Information Whole transcriptome profiling reveals major cell types in the cellular immune response against acute and chronic active Epstein‐Barr virus infection Huaqing Zhong1, Xinran Hu2, Andrew B. Janowski2, Gregory A. Storch2, Liyun Su1, Lingfeng Cao1, Jinsheng Yu3, and Jin Xu1 Department of Clinical Laboratory1, Children's Hospital of Fudan University, Minhang District, Shanghai 201102, China; Departments of Pediatrics2 and Genetics3, Washington University School of Medicine, Saint Louis, Missouri 63110, United States. Supplementary information includes the following: 1. Supplementary Figure S1: Fold‐change and correlation data for hyperactive and hypoactive genes. 2. Supplementary Table S1: Clinical data and EBV lab results for 110 study subjects. 3. Supplementary Table S2: Differentially expressed genes between AIM vs. Healthy controls. 4. Supplementary Table S3: Differentially expressed genes between CAEBV vs. Healthy controls. 5. Supplementary Table S4: Fold‐change data for 303 immune mediators. 6. Supplementary Table S5: Primers used in qPCR assays. Supplementary Figure S1. Fold‐change (a) and Pearson correlation data (b) for 10 cell markers and 61 hypoactive and hyperactive genes identified in subjects with acute EBV infection (AIM) in the primary cohort. Note: 23 up‐regulated hyperactive genes were highly correlated positively with cytotoxic T cell (Tc) marker CD8A and NK cell marker CD94 (KLRD1), and 38 down‐regulated hypoactive genes were highly correlated positively with B cell, conventional dendritic cell
    [Show full text]
  • Induction of Micrornas, Mir-155, Mir-222, Mir-424 and Mir-503, Promotes Monocytic Differentiation Through Combinatorial Regulation
    Leukemia (2010) 24, 460–466 & 2010 Macmillan Publishers Limited All rights reserved 0887-6924/10 $32.00 www.nature.com/leu ‘ ORIGINAL ARTICLE Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation ARR Forrest1,2, M Kanamori-Katayama1, Y Tomaru1, T Lassmann1, N Ninomiya1, Y Takahashi1, MJL de Hoon1, A Kubosaki1, A Kaiho1, M Suzuki1, J Yasuda1, J Kawai1, Y Hayashizaki1, DA Hume3 and H Suzuki1 1LSA Technology Development Unit, Omics Science Center, RIKEN Yokohama Institute, Yokohama, Kanagawa, Japan; 2The Eskitis Institute for Cell and Molecular Therapies, Griffith University, Brisbane, Queensland, Australia and 3The Roslin Institute, Royal (Dick) School of Veterinary Studies, The University of Edinburgh, Roslin, UK Acute myeloid leukemia (AML) involves a block in terminal that might promote differentiation. MicroRNAs are short 21–22 differentiation of the myeloid lineage and uncontrolled prolif- nucleotide RNA molecules that cause translational repression eration of a progenitor state. Using phorbol myristate acetate and degradation of multiple mRNAs by binding target sequences (PMA), it is possible to overcome this block in THP-1 cells 0 5 (an M5-AML containing the MLL-MLLT3 fusion), resulting in in their 3 UTRs. Multiple microRNAs are implicated in differentiation to an adherent monocytic phenotype. As part of differentiation of cell lineages including skeletal muscle, FANTOM4, we used microarrays to identify 23 microRNAs that adipocytes and neurons6–8 and in mammals, the microRNA are regulated by PMA. We identify four PMA-induced micro- subsystem is essential for embryonic development. Dicer RNAs (mir-155, mir-222, mir-424 and mir-503) that when over- is required for differentiation of embryonic stem cells,9 Dicer expressed cause cell-cycle arrest and partial differentiation and (À/À) knockouts are embryonic lethal10 and Ago2 (À/À) when used in combination induce additional changes not seen 11 by any individual microRNA.
    [Show full text]
  • Noncoding Rnas As Novel Pancreatic Cancer Targets
    NONCODING RNAS AS NOVEL PANCREATIC CANCER TARGETS by Amy Makler A Thesis Submitted to the Faculty of The Charles E. Schmidt College of Science In Partial Fulfillment of the Requirements for the Degree of Master of Science Florida Atlantic University Boca Raton, FL August 2018 Copyright 2018 by Amy Makler ii ACKNOWLEDGEMENTS I would first like to thank Dr. Narayanan for his continuous support, constant encouragement, and his gentle, but sometimes critical, guidance throughout the past two years of my master’s education. His faith in my abilities and his belief in my future success ensured I continue down this path of research. Working in Dr. Narayanan’s lab has truly been an unforgettable experience as well as a critical step in my future endeavors. I would also like to extend my gratitude to my committee members, Dr. Binninger and Dr. Jia, for their support and suggestions regarding my thesis. Their recommendations added a fresh perspective that enriched our initial hypothesis. They have been indispensable as members of my committee, and I thank them for their contributions. My parents have been integral to my successes in life and their support throughout my education has been crucial. They taught me to push through difficulties and encouraged me to pursue my interests. Thank you, mom and dad! I would like to thank my boyfriend, Joshua Disatham, for his assistance in ensuring my writing maintained a logical progression and flow as well as his unwavering support. He was my rock when the stress grew unbearable and his encouraging words kept me pushing along.
    [Show full text]
  • Expression and Change of Mirs 145, 221 and 222 in Hypertensive Subjects Treated with Enalapril, Losartan Or Olmesartan
    biomedicines Article Expression and Change of miRs 145, 221 and 222 in Hypertensive Subjects Treated with Enalapril, Losartan or Olmesartan Giuseppe Mandraffino 1,2,3,*,† , Alberto Lo Gullo 4,*,† , Maria Cinquegrani 1, Angela D’Ascola 3, Davide Sinicropi 1, Egidio Imbalzano 1 , Giuseppe Blando 1, Giuseppe Maurizio Campo 3, Carmela Morace 1, Clemente Giuffrida 4, Salvatore Campo 5, Giovanni Squadrito 1,‡ and Michele Scuruchi 2,3,‡ 1 Internal Medicine Unit, Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy; [email protected] (M.C.); [email protected] (D.S.); [email protected] (E.I.); [email protected] (G.B.); [email protected] (C.M.); [email protected] (G.S.) 2 Lipid Center, Internal Medicine Unit, University of Messina, 98122 Messina, Italy; [email protected] 3 Laboratory of Clinical Biochemistry, Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy; [email protected] (A.D.); [email protected] (G.M.C.) 4 IRCCS Neurolesi Bonino Pulejo, 98123 Messina, Italy; [email protected] 5 Laboratory of Molecular Biology, Department of Biomedical and Dental Sciences and Morphofunctional Images, University of Messina, 98122 Messina, Italy; [email protected] * Correspondence: gmandraffi[email protected] (G.M.); [email protected] (A.L.G.) † These authors equally contributed to this work: co-first authors. ‡ These authors equally contributed to this work: both senior authors. Citation: Mandraffino, G.; Lo Gullo, Abstract: miR profile could be associated to CV risk, and also to prognosis/outcome in response to A.; Cinquegrani, M.; D’Ascola, A.; Sinicropi, D.; Imbalzano, E.; Blando, therapeutic approach. We aimed to evaluate if anti-hypertensive drugs enalapril, losartan or olmesar- G.; Campo, G.M.; Morace, C.; tan have effects on monocyte miR profile in essential hypertensives without target organ involvement.
    [Show full text]
  • Dynamic and Modularized Microrna Regulation and Its Implication in Human Cancers
    www.nature.com/scientificreports OPEN Dynamic and Modularized MicroRNA Regulation and Its Implication in Human Cancers Received: 8 February 2017 Jiang Shu1, Bruno Vieira Resende e Silva1, Tian Gao1, Zheng Xu2,3 & Juan Cui1 Accepted: 26 September 2017 MicroRNA is responsible for the fne-tuning of fundamental cellular activities and human disease Published: xx xx xxxx development. The altered availability of microRNAs, target mRNAs, and other types of endogenous RNAs competing for microRNA interactions refects the dynamic and conditional property of microRNA- mediated gene regulation that remains under-investigated. Here we propose a new integrative method to study this dynamic process by considering both competing and cooperative mechanisms and identifying functional modules where diferent microRNAs co-regulate the same functional process. Specifcally, a new pipeline was built based on a meta-Lasso regression model and the proof-of-concept study was performed using a large-scale genomic dataset from ~4,200 patients with 9 cancer types. In the analysis, 10,726 microRNA-mRNA interactions were identifed to be associated with a specifc stage and/or type of cancer, which demonstrated the dynamic and conditional miRNA regulation during cancer progression. On the other hands, we detected 4,134 regulatory modules that exhibit high fdelity of microRNA function through selective microRNA-mRNA binding and modulation. For example, miR-18a-3p, −320a, −193b-3p, and −92b-3p co-regulate the glycolysis/gluconeogenesis and focal adhesion in cancers of kidney, liver, lung, and uterus. Furthermore, several new insights into dynamic microRNA regulation in cancers have been discovered in this study. Mature microRNAs (miRNAs) are typically 20–25 nucleotides long.
    [Show full text]
  • Inhibition of Mir-222 by Oncolytic Adenovirus-Encoded Mirna Sponges Promotes Viral Oncolysis and Elicits Antitumor Effects in Pancreatic Cancer Models
    cancers Article Inhibition of miR-222 by Oncolytic Adenovirus-Encoded miRNA Sponges Promotes Viral Oncolysis and Elicits Antitumor Effects in Pancreatic Cancer Models Giulia Raimondi 1, Sabrina Gea-Sorlí 1,2, Marc Otero-Mateo 1 and Cristina Fillat 1,2,3,* 1 Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036 Barcelona, Spain; [email protected] (G.R.); [email protected] (S.G.-S.); [email protected] (M.O.-M.) 2 Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 08036 Barcelona, Spain 3 Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB), 08036 Barcelona, Spain * Correspondence: cfi[email protected] Simple Summary: Oncolytic adenoviruses are replication-competent viruses engineered for use in cancer treatment. However, the transformation of cancer cells defines a scenario in which the viruses are not adapted to replicate. During tumorigenesis, a large number of miRNAs are deregulated, modulating the expression of genes with essential roles in carcinogenesis and with potential effects on adenoviral propagation. Here we show how OncomiRs can impact adenoviral activity, identifying miR-222 as a limiting factor. Of notice, by genetically engineering a therapeutic adenovirus with miR-222 sponges (AdNuPAR-E-miR222-S), we reduced the latter miRNA content, while enhancing adenoviral fitness, increasing cytotoxicity, and sustaining tumor growth control in xenografts. Citation: Raimondi, G.; Gea-Sorlí, S.; Abstract: Oncolytic adenoviruses (OA) are envisioned as a therapeutic option for patients with cancer, Otero-Mateo, M.; Fillat, C. Inhibition designed to preferentially replicate in cancer cells. However, the high number of genetic alterations in of miR-222 by Oncolytic tumors can generate a context in which adenoviruses have difficulties replicating.
    [Show full text]
  • Distinct Requirements of Micrornas in NK Cell Activation, Survival, and Function
    The Journal of Immunology Distinct Requirements of MicroRNAs in NK Cell Activation, Survival, and Function Natalie A. Bezman,*,† Elizabeth Cedars,*,†,‡ David F. Steiner,*,†,‡ Robert Blelloch,x,{ David G. T. Hesslein,*,† and Lewis L. Lanier*,†,‡ MicroRNAs (miRNAs) are small noncoding RNAs that have recently emerged as critical regulators of gene expression within the immune system. In this study, we used mice with conditional deletion of Dicer and DiGeorge syndrome critical region 8 (Dgcr8) to dissect the roles of miRNAs in NK cell activation, survival, and function during viral infection. We developed a system for deletion of either Dicer or Dgcr8 in peripheral NK cells via drug-induced Cre activity. We found that Dicer- and Dgcr8-deficient NK cells were significantly impaired in survival and turnover, and had impaired function of the ITAM-containing activating NK cell receptors. We further demonstrated that both Dicer- and Dgcr8-dependent pathways were indispensable for the expansion of Ly49H+ NK cells during mouse cytomegalovirus infection. Our data indicate similar phenotypes for Dicer- and Dgcr8-deficient NK cells, which strongly suggest that these processes are regulated by miRNAs. Thus, our findings indicate a critical role for miRNAs in controlling NK cell homeostasis and effector function, with implications for miRNAs regulating diverse aspects of NK cell biology. The Journal of Immunology, 2010, 185: 3835–3846. atural killer cells are a key component of the innate im- complexes results in recruitment and activation of protein tyrosine mune system, providing early cellular defense against kinases, which initiate the signaling cascade, resulting in secretion N viruses and intracellular pathogens, and contributing to of effector cytokines, such as IFN-g, and target cell cytotoxicity.
    [Show full text]